Agios (AGIO) Q3 2026 earnings review
Agios thalassemia sales rise fast, but regulators delay its sickle-cell review
Strong patient retention in thalassemia is lifting Agios's sales, even as regulators delayed its next major drug approval. Total product revenue for the rare blood disorder specialist reached $55 million, and by our math U.S. sales rose 36% from last quarter after stripping out a prior $5 million inventory benefit. Chief executive Brian Goff credited expanding demand for Aqvesme, its U.S. thalassemia pill, where about 75% of patients stay on therapy after six months.
| U.S. sales, excluding Q2 stocking benefit | +36% from last quarter by our math ($48.7M) |
|---|---|
| Aqvesme six-month patient retention | ~75% first time disclosed (619 cumulative prescriptions) |
| Sickle cell FDA target decision date | Feb 1, 2027 delayed 3 months from Nov 1, 2026 |
| Profitability outlook, excluding one-offs | 2028 target backed by cutting over 35% of research roles |
⚖️ Verdict: 🟢 Bullish
The story got better because proving that three-quarters of thalassemia patients stay on treatment removes the biggest doubt about the current launch and supports a new 2028 target for profitability excluding one-offs, backed by cutting over 35% of research staff. The bad news: the Food and Drug Administration pushed its sickle cell decision back three months to February 2027 to evaluate whether a liver-safety program is required, while quarterly new thalassemia prescriptions slowed again to 177.
The question now is whether the two-quarter dip in new thalassemia prescriptions is a normal shift toward less-severe patients or an early sign that the easiest-to-reach patient pool is filling up. If retention stays near 75% and the 48 pending forms convert, quarterly revenue will keep climbing; if new starts fall further, growth will stall before sickle cell launches. Fourth-quarter U.S. sales and the February FDA decision will settle both debates.
🐂 Bull Case
Seventy-Five Percent of Patients Stay on Aqvesme
"The third quarter was a record for our product revenue, outperforming our entire 2025 total in just three months," chief executive Brian Goff said. Aqvesme, the company's U.S. brand name for its pill mitapivat in the inherited blood disorder thalassemia, drove that growth. For the first time since the January launch, Agios reported how many patients stay on the drug, easing a major concern while Goff noted "where broadening demand is translating into a durable base of patients on therapy".
- Six-month patient retention on Aqvesme: approximately 75%
- U.S. net revenue: $48.7 million, up 20% from last quarter as reported
- Underlying U.S. net revenue growth: up 36% from last quarter by our math, after stripping out last quarter's $5 million one-time inventory stocking benefit
This retention rate matters because doctors check after six months whether the pill is working before renewing it. Keeping three out of four patients builds a recurring revenue base, which explains why underlying U.S. sales jumped by more than a third even as new prescriptions slowed.
What to watch: fourth-quarter U.S. net revenue and any update on twelve-month retention. Continued sequential dollar growth of $8 million or more would confirm that early patients are staying on treatment beyond the six-month mark.
Early Access Programs Lift Overseas Sales
Outside the United States, Agios sells the same rare blood disorder pill under the brand name Pyrukynd through regional partners. Those partners — Avanzanite Bioscience in Europe and NewBridge Pharmaceuticals in the Gulf Cooperation Council region — allow the drugmaker to collect sales without building its own foreign sales force, though order timing in the Gulf had made quarterly results uneven.
Overseas net revenue rose 74% from last quarter to $6.6 million, up from $3.8 million in the second quarter and $0.6 million a year ago. Agios said early access programs in Europe drove the increase after European regulators approved Pyrukynd for thalassemia in late May 2026.
What to watch: fourth-quarter overseas net revenue as European countries move from early access to formal country-by-country reimbursement. Holding above $6.6 million would show that steady European patient demand is replacing lumpy ordering in the Gulf.
In-Licensed Pipeline Drug Supports Twice-Yearly Dosing
Since halting its backup drug tebapivat earlier this year, Agios has relied on mitapivat for all current sales while licensing outside drugs to rebuild its pipeline. One of those additions is AG-236, an experimental treatment for polycythemia vera, a rare disease where the bone marrow makes too many red blood cells.
The company announced that first clinical results from a Phase 1 study of AG-236 in healthy volunteers "support every-six-month dosing in polycythemia vera" and were accepted for presentation at the December hematology conference. Convenient twice-yearly dosing gives Agios a credible second medicine behind mitapivat as it prepares to start Phase 2 testing.
What to watch: the full Phase 1 data presentation at the American Society of Hematology meeting in December 2026 and confirmation that the Phase 2 trial has begun. Clean safety data would validate the company's shift toward licensed pipeline assets.
🐻 Bear Case
FDA Delays the Sickle Cell Decision to February
Sickle cell disease is an inherited disorder that deforms red blood cells, and Goff called it the company's "largest indication opportunity with mitapivat" while stating that Agios is "launch-ready ahead of our PDUFA goal date of February 1, 2027". Bullish investors point to new data from the RISE UP Phase 3 trial showing hemoglobin improvements "for up to 115 weeks (over two years) with continued treatment".
However, the U.S. Food and Drug Administration pushed its review deadline back by three months from November 1, 2026, to February 1, 2027. Regulators asked for more information "to evaluate whether a REMS is necessary for mitapivat in sickle cell disease" — a safety program requiring liver tests — and treated the company's reply as a major amendment.
That delay pushes first sickle cell revenue into 2027 and shows that liver safety monitoring could carry over into a much larger patient population. Meanwhile, selling, general and administrative expenses — the cost of the sales force and corporate overhead — rose 37% from a year ago to $56.5 million as the company staffed up early.
What to watch: the FDA approval decision and final label on or before February 1, 2027. A mandatory liver-monitoring program with frequent blood draws would slow doctor adoption in sickle cell disease relative to an unrestricted label.
New Aqvesme Prescriptions Slowed for a Second Quarter
To prescribe Aqvesme in the United States, doctors must be certified under a Risk Evaluation and Mitigation Strategy (REMS), an FDA-mandated liver safety program, and patients must complete an Agios start form. The company tracks cumulative completed start forms to show expanding demand in thalassemia.
- New prescriptions with completed start forms in Q3: 177, down 11.5% from 200 in Q2 and 242 in Q1
- Cumulative completed prescriptions as of September 30: 619, up from 442 in Q2
- Additional prescriptions with start forms still in process: 48
While the cumulative total keeps rising, the quarterly flow of new patients has fallen for two quarters in a row as the launch moves past the easiest-to-reach patients. Because each start form takes 10 to 12 weeks to turn into paid refills, a slower inflow today caps how fast U.S. thalassemia revenue can grow in early 2027.
What to watch: whether Agios discloses fourth-quarter prescription numbers or retires the figure as previously planned. If the company stops reporting prescriptions, sequential U.S. revenue growth will be the only check on whether new patient additions have stabilized.
Risks this quarter didn't answer
Three standing questions around product sales splits, future launch disclosures, and sickle cell economics received no new figures in the third-quarter release.
- Pyrukynd revenue in pyruvate kinase deficiency: Agios reported combined U.S. sales of $48.7 million without splitting out its original indication, leaving no way to check its $45 million to $50 million full-year target until the annual filing.
- Future prescription reporting: the release did not state whether third-quarter prescription counts are the final disclosure before switching solely to revenue.
- Sickle cell pricing and payer mix: with labeling talks ongoing ahead of the February 2027 deadline, the company gave no update on pricing or Medicaid rebates.
👓 Other Themes
Agios Cuts Over a Third of Research Roles
Following a review of its operating model over 2026, the biotechnology group will cut its research and development headcount by more than 100 roles by the end of the year, a reduction of more than 35% compared with 2025. Third-quarter research and development spending already fell 15.3% from a year ago to $73.5 million on lower trial and process development costs, and Agios expects the layoff savings to arrive in 2027.
💲 Other KPIs
Cash, cash equivalents, and marketable securities fell by $57.8 million from last quarter, down from $964.8 million in the second quarter and $1.16 billion at year-end 2025. The quarterly cash drop narrowed from $80.7 million in the second quarter because product revenue rose and last quarter included a $25 million licensing fee.
Accounts receivable — money owed by drug distributors for shipped medicine — rose 25.6% from last quarter's $20.1 million and more than doubled from $10.6 million at the end of 2025. That increase moved in step with the 23.8% quarterly rise in product revenue, showing normal cash collection as the thalassemia launch scales.
Weighted-average common shares rose 2.7% from a year ago and 0.4% from the second quarter's 59.5 million. Because the drugmaker funds its launches from its existing cash pile rather than selling new stock, share count growth comes only from employee stock plans.
🔮 Guidance
New. Agios set a formal timeline to reach profitability excluding one-offs in 2028, after previously stating only that its cash pile provided financial independence. By our math, its existing plan to keep 2026 operating expenses roughly even with 2025's $526.2 million (excluding a $25 million licensing fee) leaves $132.5 million for the fourth quarter, matching the third quarter's $132.5 million.
❓ Key Questions
What requirements is the FDA considering for the sickle cell REMS?
The FDA delayed the sickle cell review by three months to evaluate whether a safety program is needed. Investors need to know if regulators want the same monthly liver tests used in thalassemia or stricter rules that could deter doctors.
How much of U.S. revenue came from Aqvesme versus Pyrukynd?
Agios reported $48.7 million in combined U.S. sales without breaking out its older pyruvate kinase deficiency indication. Without that split, outsiders cannot verify the $45 million to $50 million full-year target for the older business or measure exact thalassemia sales.
Will Agios continue reporting Aqvesme prescriptions and retention rates?
Management previously planned to stop reporting prescription counts after the third quarter, yet introduced a new 48-prescription in-process figure and a 75% six-month retention number. Investors need to know which patient metrics will be reported in the fourth quarter.
How many dollars will the research layoffs save in 2027?
Cutting more than 100 research roles — over 35% of the research workforce — underpins the new 2028 profitability target. Management did not disclose the one-time severance charges for 2026 or the annual dollar savings expected in 2027.